Insiders, Venture, Venture Capital

By the numbers for 2018: The top 100 venture players in biotech — and who’s been paying the piper in cancer R&D?

The explosion of oncology R&D over the past few years has had a dramatic impact on a variety of fronts, all clearly illustrated in these lineups of the top 100 venture investors in biotech from Chris Dokomajilar at DealForma.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->